<DOC>
	<DOC>NCT01451905</DOC>
	<brief_summary>To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease</brief_summary>
	<brief_title>GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>4.3 Inclusion Criteria Caucasians above 18 years of age Plaque psoriasis PASI score &gt;10 No treatment or stable treatment of psoriasis during at least 3 months before inclusion Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2 Normal blood pressure Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma halflife) 4.4 Exclusion Criteria Psoriasis arthritis Fasting plasma glucose &gt; 7.5 mmol/L or HbA1c &gt; 7.5% Type 1 diabetes Treatment for type 2 diabetes with GLP1based medicine (DDP4inhibitors or GLP1receptoragonists) Heart failure, NYHA class IIIIV Uraemia, endstage renal disease, or any other cause of impaired renal function with screatinine &gt;150 ÂµM and/or albuminuria Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) &gt;2 x upper normal serum levels) Anaemia Acute or chronic pancreatitis Struma or thyroid cancer Pregnancy or breast feeding Inability to complete the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>